Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 4/20 | 0.65 |
| ▸ | EDNRA | P25101 | 3/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6038532 | 0.91 | CCR4 (0.79) | CCR4EDNRA | |
| SCHEMBL6038637 | 0.89 | CCR4 (0.68) | CCR4EDNRAABCB11TSHRSMN1; SMN2 | |
| SCHEMBL6038970 | 0.88 | CCR4 (0.59) | CCR4EDNRAPIK3CDMAPT | |
| SCHEMBL6039078 | 0.88 | CCR4 (0.84) | CCR4EDNRAABCB11TSHR | |
| SCHEMBL6038409 | 0.83 | CCR4 (0.71) | CCR4EDNRAABCB11TSHR | |
| SCHEMBL6039055 | 0.83 | CCR4 (0.71) | CCR4EDNRAABCB11TSHRSMN1; SMN2 | |
| SCHEMBL6038439 | 0.81 | CCR4 (0.72) | CCR4EDNRATSHRSMN1; SMN2 | |
| SCHEMBL6038499 | 0.80 | CCR4 (0.82) | CCR4EDNRA | |
| SCHEMBL6038535 | 0.79 | CCR4 (0.65) | CCR4EDNRATSHRMAPTSMN1; SMN2 | |
| SCHEMBL6038846 | 0.79 | CCR4 (1.00) | CCR4EDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1541563-A1 | CCR4 ANTAGONIST AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004010-A1 | Ccr4 antagonist and medical use thereof | CCR4, CCR1, CCR9 | CCR4 1/4885EDNRA 512/4885PIK3CD 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.